BR0012325A - Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo - Google Patents
Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeoInfo
- Publication number
- BR0012325A BR0012325A BR0012325-0A BR0012325A BR0012325A BR 0012325 A BR0012325 A BR 0012325A BR 0012325 A BR0012325 A BR 0012325A BR 0012325 A BR0012325 A BR 0012325A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- preventing
- molecules
- transcription
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14305999P | 1999-07-09 | 1999-07-09 | |
PCT/US2000/017670 WO2001004313A1 (en) | 1999-07-09 | 2000-06-27 | Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0012325A true BR0012325A (pt) | 2002-05-21 |
Family
ID=22502421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0012325-0A BR0012325A (pt) | 1999-07-09 | 2000-06-27 | Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1194556A1 (es) |
JP (1) | JP2003504061A (es) |
KR (1) | KR20020030780A (es) |
CN (1) | CN1360631A (es) |
AU (1) | AU783681B2 (es) |
BR (1) | BR0012325A (es) |
CA (1) | CA2378653A1 (es) |
IL (1) | IL147026A0 (es) |
MX (1) | MXPA01013462A (es) |
WO (1) | WO2001004313A1 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
EP1555317B1 (en) | 1998-03-20 | 2011-09-28 | Commonwealth Scientific And Industrial Research Organisation | Synthetic genes and genetic constructs comprising the same |
CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
US7601494B2 (en) | 1999-03-17 | 2009-10-13 | The University Of North Carolina At Chapel Hill | Method of screening candidate compounds for susceptibility to biliary excretion |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
AU2001249170A1 (en) * | 2000-03-13 | 2001-09-24 | Aptagen | Method for modifying a nucleic acid |
US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
WO2002077609A2 (en) | 2001-03-26 | 2002-10-03 | Message Pharmaceuticals, Inc. | Identification of compounds for the treatment or prevention of proliferative diseases |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
ES2240745T3 (es) | 2001-06-05 | 2005-10-16 | Curevac Gmbh | Composicion farmaceutica que contiene un arnm estabilizado y optimizado para la traduccion, adecuada como vacuna y como regenerante de tejidos. |
US7897382B2 (en) | 2001-10-22 | 2011-03-01 | Alnylam Pharmaceuticals, Inc. | Transfection kinetics and structural promoters |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
US20040180438A1 (en) | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
WO2004094654A2 (en) * | 2003-04-22 | 2004-11-04 | Nucleonics, Inc. | Transfection kinetics and structural promoters |
AU2005212433B2 (en) | 2003-05-23 | 2010-12-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA) |
WO2005078848A2 (en) | 2004-02-11 | 2005-08-25 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes |
AU2005222965B8 (en) | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
EP1747022A4 (en) | 2004-04-23 | 2010-03-31 | Univ Columbia | INHIBITION OF HAIRLESS GENE PROTEIN-ASSOCIATED MRNA (NO HAIR) |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP1782321A4 (en) | 2004-07-23 | 2009-11-04 | Univ North Carolina | METHOD AND MATERIALS FOR DETERMINING PAIN SENSITIVITY AND PREDICTING AND TREATING SUFFERING INTERFERENCE |
WO2007011702A2 (en) | 2005-07-15 | 2007-01-25 | The University Of North Carolina At Chapel Hill | Use of egfr inhibitors to prevent or treat obesity |
AU2006298844B2 (en) | 2005-09-20 | 2012-01-12 | Basf Plant Science Gmbh | Methods for controlling gene expression using ta-siRAN |
BRPI0806436A2 (pt) | 2007-01-26 | 2011-09-06 | Univ Lousville Res Foundation Inc | modificação de componentes exossomais para uso como uma vacina |
CA2681323A1 (en) | 2007-03-21 | 2008-09-25 | Brookhaven Science Associates, Llc | Combined hairpin-antisense compositions and methods for modulating expression |
EP3766976A1 (en) | 2009-12-18 | 2021-01-20 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
CA2789125A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
WO2013090648A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
BR112014016870A2 (pt) | 2012-01-09 | 2017-06-27 | Huesken Dieter | composições orgânicas para tratar doenças relacionadas com beta-catenina |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP3501550A1 (en) | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
SI2922554T1 (sl) | 2012-11-26 | 2022-06-30 | Modernatx, Inc. | Terminalno modificirana RNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
EP3423568A4 (en) | 2016-03-04 | 2019-11-13 | University Of Louisville Research Foundation, Inc. | METHOD AND COMPOSITIONS FOR EX-VIVO REPRODUCTION OF VERY SMALL EMBRYONAL STEM CELLS (VSELS) |
WO2020236597A1 (en) * | 2019-05-17 | 2020-11-26 | Massachusetts Institute Of Technology | Engineered post-poly a signal rna and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587300A (en) * | 1994-04-26 | 1996-12-24 | Wisconsin Ulumni Research Foundation | Method to increase regulatory molecule production |
US5888774A (en) * | 1994-12-19 | 1999-03-30 | Cangene Corporation | Recombinant DNA molecules and expression vectors for erythropoietin |
US6022863A (en) * | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
AU8916098A (en) * | 1997-08-22 | 1999-03-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Polynucleotide inhibition of rna destabilization and sequestration |
EP1021549A2 (en) * | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
-
2000
- 2000-06-27 CA CA002378653A patent/CA2378653A1/en not_active Abandoned
- 2000-06-27 KR KR1020027000339A patent/KR20020030780A/ko not_active Application Discontinuation
- 2000-06-27 AU AU58937/00A patent/AU783681B2/en not_active Ceased
- 2000-06-27 CN CN00810072A patent/CN1360631A/zh active Pending
- 2000-06-27 JP JP2001509517A patent/JP2003504061A/ja active Pending
- 2000-06-27 IL IL14702600A patent/IL147026A0/xx unknown
- 2000-06-27 WO PCT/US2000/017670 patent/WO2001004313A1/en not_active Application Discontinuation
- 2000-06-27 EP EP00944916A patent/EP1194556A1/en not_active Withdrawn
- 2000-06-27 BR BR0012325-0A patent/BR0012325A/pt not_active IP Right Cessation
- 2000-06-27 MX MXPA01013462A patent/MXPA01013462A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN1360631A (zh) | 2002-07-24 |
MXPA01013462A (es) | 2002-07-02 |
CA2378653A1 (en) | 2001-01-18 |
EP1194556A1 (en) | 2002-04-10 |
AU5893700A (en) | 2001-01-30 |
AU783681B2 (en) | 2005-11-24 |
IL147026A0 (en) | 2002-08-14 |
JP2003504061A (ja) | 2003-02-04 |
WO2001004313A1 (en) | 2001-01-18 |
KR20020030780A (ko) | 2002-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0012325A (pt) | Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo | |
EP3359677B1 (en) | Compositions and methods for treating fragile x syndrome and related syndromes | |
WO2018179578A1 (ja) | ゲノム編集によるエクソンスキッピング誘導方法 | |
EP2239327A3 (en) | Method for in vitro recombination | |
CN107532162A (zh) | 用于利用寡核苷酸编辑细胞中核酸的组合物和方法 | |
DE60329220D1 (de) | Antisense-entwurf | |
GB2397062A (en) | RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA) | |
GB2397818A (en) | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid | |
EP2014776A3 (en) | Diagnosis of diseases associated with DNA transcription | |
BR9914773A (pt) | Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica | |
EP2631292A3 (en) | Human microRNAs and methods for inhibiting same | |
IL166546A (en) | Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene | |
ATE239090T1 (de) | Methode zum generieren von einzelsträngigen dna molekülen | |
WO2007031877A3 (en) | Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification | |
EP3040423A3 (en) | Microrna and uses thereof | |
DE69934227D1 (de) | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide | |
WO1998026093A3 (en) | Fluorescent nucleotide analog hairpin formation for detection of nucleic acid hybridization | |
Bah et al. | The telomeric transcriptome: from fission yeast to mammals | |
WO2000078968A3 (en) | Nucleotide sequences of moraxella catarrhalis genome | |
WO2000073764A3 (en) | Composition and methods for the therapeutic use of an atonal-associated sequence | |
WO2004001013A3 (en) | Inhibition of gene expression in vertebrates using double-stranded rna (rnai) | |
EP1268507A4 (en) | ANTISENSE MODULATION OF THE EXPRESSION OF THE TRANSCRIPTION FACTOR E2F-1 | |
HUP0101355A2 (hu) | Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák | |
WO2001071036A3 (en) | Methods of preparing amplified nucleic acid molecules | |
WO2004070057A3 (de) | Verwendung eines neuen polymorphismus im hsgk1-gen zur diagnose der hypertonie und verwendung der sgk-genfamilie zur diagnose und therapie des long-q/t-syndroms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009. |